Press release

Date 18 November 2026
Contact Investor Relations: investors@galenica.com / +41 58 852 85 31
Media Relations: media@galenica.com / +41 58 852 85 17

Topic Galenica strengthens its consumer healthcare business

Verfora acquires majority stake in distribution partner Qpharma

- **With Qpharma, Verfora is gaining an established Polish pharmaceutical distributor with a strong distribution platform in Central and Eastern Europe.**
- **Qpharma already distributes Verfora products.**
- **The acquisition expands Verfora's distribution base and creates further opportunities for development in Central and Eastern Europe.**

Verfora is acquiring a majority stake in the Polish pharmaceutical distributor Qpharma. With the acquisition of 51% of the shares, Verfora is expanding its distribution network to include a long-standing distribution partner and thus an established distribution platform. At the same time, the company is gaining an important partner along its own value chain and thus, alongside Austria, a second distribution network in Europe. The combination of strong brands, marketing expertise and local distribution know-how creates additional development opportunities for its existing consumer healthcare business.

Established distribution platform

Qpharma is a family-run company based in Poland that has been active in the healthcare market for over 20 years and generated sales in the low double-digit million euro range. The company specialises in marketing, promotion and distribution of prescription-only drugs, OTC products and dietary supplements. Qpharma has exclusive distribution rights for various brands in Poland, the Czech Republic and Slovakia.

Qpharma has built up an established market position in Eastern Europe and has long-standing customer relationships as well as extensive experience in marketing and distribution of healthcare products. The company has been working with Verfora for many years and is responsible for the distribution of various Verfora products, including Perskindol in Poland and the Czech Republic and, since 2025, Padma products in Poland.

Acquisition of a long-standing partner

The acquisition brings together Verfora's brand and marketing expertise with Qpharma's established distribution platform and expands Verfora's value chain. Qpharma's attractive distribution licences also offer further development potential. Following the acquisition, Qpharma will continue to be managed by the current CEO, Zbyszek Czop, and developed together with Verfora.

Galenica Ltd.
Untermattweg 8 | P.O. Box | CH-3001 Bern
+41 58 852 81 11 | info@galenica.com | galenica.com

"Qpharma has been an important partner for our brands for many years with an excellent understanding of our products, quality standards and its customers' needs. With this acquisition, we are further developing a successful collaboration and creating the conditions to make even better use of our combined potential," says Stefan Wälti, CEO of Verfora.

Completion of the transaction is subject to regulatory approvals. The parties have agreed not to disclose the sale price.

Dates for the diary

21 January 2027	Galenica Group sales update 2026
09 March 2027	Annual results for 2026 and annual media & analyst conference of the Galenica Group
22 April 2027	Annual General Meeting of Galenica Ltd.

For further information, please contact

Media Relations
Nina Amann, Lead Media Relations
Tel. +41 58 852 85 17
E-mail: media@galenica.com

Investor Relations
Florian Urech, Head of Investor Relations
Tel. +41 58 852 85 31
E-mail: investors@galenica.com

Galenica: Switzerland's leading healthcare network

The Galenica Group is Switzerland's leading integrated healthcare network. With more than 20 companies, it is active along the entire healthcare value chain. The network includes the densest pharmacy network in Switzerland with over 380 locations, including the Amavita and Sun Store pharmacies and our partner Coop Vitality. Galenica is the market leader in wholesale and pharmaceutical logistics: one in two medication packs sold in Switzerland passes through Galexis and Alloga logistics. As the Swiss market leader, Verfora also develops and distributes its own healthcare products as well as the brands of business partners. The Galenica Group's portfolio is supplemented by services in the home care sector, diagnostics and digital solutions for healthcare professionals. Galenica has more than 8,000 employees and generated net sales of CHF 4.1 billion in 2025. The shares of Galenica Ltd. (GALE) are listed on SIX Swiss Exchange.
www.galenica.com

Verfora

Verfora is one of the leading providers in the Swiss consumer healthcare market with a broad portfolio of strong brands for health and well-being. These include products in the categories painkillers, vitamins and minerals, coughs and colds and digestive health. Verfora is part of the Galenica network.
www.verfora.ch